Similary, in 8907 patients with stable coronary artery disease from the EUROPA trial [260], the ACE I/D polymorphism was not associated with ACE inhibitor treatment benefit (i.e. no association with cardiovascular morbidity and mortality during follow-up). This evidence concerns the gene ACE and coronary artery disorder.